Cannabinoid antagonist SLV326 induces convulsive seizures and changes in the ...

Cannabinoid CB1 antagonists have been investigated for possible treatment of e.g. obesity-related disorders. However, clinical application was halted due to their symptoms of...大麻素CB1受体拮抗剂（Cannabinoid CB1 antagonists）已被研究用于肥胖相关病症等潜在适应症的治疗。然而，由于其引发的相关症状（原文未完整说明具体症状），其临床应用已被叫停。